BioDetego

BioDetego is developing the next generation of cancer diagnostics - identifying who needs chemotherapy better than traditional staging or molecular diagnostics.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Philadelphia, PA, USA
  • Currency USD
  • Founded June 2012
  • Employees 0
  • Incorporation Type LLC
  • Website http://biodetego.com

Company Summary

Existing colon cancer diagnostics provide no individualized data that identifies patients that are likely to relapse. Our test platform accurately determines patients' risk of relapse, provides 100% actionable information to guide treatment decisions, and can be developed for any cancer type. The test platform will offer payors savings by reducing undertreatment of patients in need of chemotherapy and harmful overtreatment of low risk patients.

Team

  • David Zuzga, Ph.D.
    Co-founder, CEO

    Dr. Zuzga is a research scientist and entrepreneur. His research identified “driver” metastasis biomarkers that are associated with cancer progression and this work serves as the foundation of BioDetego’s platform technology

  • Anthony Shuber
    Executive Chair

    Mr. Shuber co-founded Exact Sciences and developed the first non-invasive diagnostic test for CRC screening. Later he co-founded Predictive Biosciences and developed the first diagnostic combining protein and DNA. He has over 100 issued and pending patent applications.

Advisors

  • Robert Hrubiec
    Business Advisor
    Nicholas Siciliano
    Business Advisor
    Unconfirmed
    Massimo Cristofanilli, M.D., FACP
    Clinical Advisory Board
    Unconfirmed
  • Juan Palazzo
    Clinical Advisory Board
    GianMario Pitari, M.D., Ph.D.
    Unconfirmed

Previous Investors

  • Ben Franklin Technology Partners
    Unconfirmed
    BioAdvance
    Unconfirmed
    Peter Melley

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free